Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateGlobeNewsWire • 02/29/24
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCGlobeNewsWire • 02/29/24
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)GlobeNewsWire • 02/29/24
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business UpdateGlobeNewsWire • 02/22/24
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer ResearchPRNewsWire • 01/17/24
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare ConferencePRNewsWire • 11/20/23
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business UpdatePRNewsWire • 11/02/23
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business UpdatePRNewsWire • 10/26/23
Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/11/23
Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocksMarket Watch • 09/27/23
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib MonotherapyPRNewsWire • 09/26/23
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business UpdatePRNewsWire • 08/09/23
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer RelationshipPRNewsWire • 08/07/23
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business UpdatePRNewsWire • 05/04/23
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal CancerPRNewsWire • 03/28/23
Has Cardiff Oncology (CRDF) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 03/17/23
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdatePRNewsWire • 03/02/23
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical OfficerPRNewsWire • 02/02/23
Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology ConferencePRNewsWire • 01/10/23